12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Epizyme preclinical data

In mice subcutaneously implanted with human lymphomas that have enhancer of zeste homolog 2 (EZH2) mutations, oral E7438 led to complete tumor elimination...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >